Non-Small Cell Lung Cancer (NSCLC)

March 29th 2025

Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

March 28th 2025

Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

March 27th 2025

CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.

March 25th 2025

In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.